Advertisement

Leukocyte Cell-Derived Chemotaxin 2 Amyloidosis (ALECT2)

  • Oana Madalina Mereuta
  • Chris P. Larsen
  • Ahmet DoganEmail author
Part of the Current Clinical Pathology book series (CCPATH)

Abstract

Leukocyte cell-derived chemotaxin 2 amyloidosis (ALECT2) represents the third most common form of renal amyloidosis and has been recently recognized as a frequent cause of hepatic amyloidosis in the USA. The disease shows a restricted geographical and ethnic distribution, and the amyloid deposition in the kidney and liver commonly presents with characteristic pathological features. Nevertheless, ALECT2 amyloidosis has a relatively indolent clinical course which makes the diagnosis difficult. Therefore, an accurate typing of amyloid deposits is required for the appropriate treatment of these patients. We address in this chapter some aspects regarding the pathogenesis of the disease as well as recent advances in the diagnosis of ALECT2 amyloidosis by immunohistochemistry (IHC) and mass spectrometry (MS)-based proteomic analysis.

Keywords

Leukocyte cell-derived chemotaxin 2 (LECT2) Renal and hepatic amyloidosis Hispanic Globular amyloid Mass spectrometry (MS) 

References

  1. 1.
    Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int. 2008;74(2):218–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Murphy CL, Wang S, Kestler D, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis. 2010;56(6):1100–7.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Larsen CP, Walker PD, Weiss DT, Solomon A. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int. 2010;77(9):816–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Larsen CP, Kossmann RJ, Beggs ML, Solomon A, Walker PD. Clinical, morphologic and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int. 2014;86(2):378–82.CrossRefPubMedGoogle Scholar
  5. 5.
    Mereuta OM, Theis JD, Vrana JA, et al. Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood. 2014;123(10):1479–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515–23.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Said SM, Sethi S, Valeri AM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014;86(2):370–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Hutton HL, DeMarco ML, Magil AB, Taylor P. Renal leukocyte chemotactic factor 2 (LECT2) amyloidosis in First Nations people in Northern British Columbia, Canada: a report of 4 cases. Am J Kidney Dis. 2014;64(5):790–2.CrossRefPubMedGoogle Scholar
  9. 9.
    Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen 3rd HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010;17:101–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Yamagoe S, Yamakawa Y, Matsuo Y, et al. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett. 1996;52:9–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Hiraki Y, Inoue H, Kondo J, et al. A novel growthpromoting factor derived from fetal bovine cartilage, chondromodulin II. Purification and aminoacid sequence. J Biol Chem. 1996;271:22657–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Ovejero C, Cavard C, Périanin A, et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of β-catenin in the liver. Hepatology. 2004;40:167–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Segawa Y, Itokazu Y, Inoue N, Saito T, Suzuki K. Possible changes in expression of chemotaxin LECT2 mRNA in mouse liver after concanavalin A-induced hepatic injury. Biol Pharm Bull. 2001;24(4):425–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Yamagoe S, Mizuno S, Suzuki K. Molecular cloning of human and bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the liver. Biochim Biophys Acta. 1998;1396(1):105–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Yamagoe S, Akasaka T, Uchida T, et al. Expression of a neutrophil chemotactic protein LECT2 in human hepatocytes revealed by immunochemical studies using polyclonal and monoclonal antibodies to a recombinant LECT2. Biochem Biophys Res Commun. 1997;237(1):116–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Nagai H, Hamada T, Uchida T, Yamagoe S, Suzuki K. Systemic expression of a newly recognized protein, LECT2, in the human body. Pathol Int. 1998;48(11):882–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Uchida T, Nagai H, Gotoh K, et al. Expression pattern of a newly recognized protein, LECT2, in hepatocellular carcinoma and its premalignant lesion. Pathol Int. 1999;49(2):147–51.CrossRefPubMedGoogle Scholar
  19. 19.
    Benson MD. LECT2 amyloidosis. Kidney Int. 2010;77:757–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Sato Y, Watanabe H, Kameyama H, et al. Serum LECT2 level as a prognostic indicator in acute liver failure. Transplant Proc. 2004;36(8):2359–61.CrossRefPubMedGoogle Scholar
  21. 21.
    Sato Y, Watanabe H, Kameyama H, et al. Changes in serum LECT 2 levels during the early period of liver regeneration after adult living related donor liver transplantation. Transplant Proc. 2004;36(8):2357–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Murphy C, Wang S, Kestler D, Larsen C, Benson D, Weiss D, Solomon A. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis. Amyloid. 2011;18 Suppl 1:223–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Yamagoe S, Kameoka Y, Hashimoto K, Mizuno S, Suzuki K. Molecular cloning, structural characterization, and chromosomal mapping of the human LECT2 gene. Genomics. 1998;48(3):324–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Dogan A, Theis JD, Vrana JA, et al. Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2) (abstract OP-058). Amyloid. 2010;17 Suppl 1:69–70.Google Scholar
  25. 25.
    Kameoka Y, Yamagoe S, Hatano Y, Kasama T, Suzuki K. Val58Ile polymorphism of the neutrophil chemoattractant LECT2 and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 2000;43(6):1419–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Buck FS, Koss MN, Sherrod AE, Wu A, Takahashi M. Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol. 1989;2(4):372–7.PubMedGoogle Scholar
  27. 27.
    Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol. 1991;22:904–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Damlaj M, Amre R, Wong P, How J. Hepatic ALECT2-amyloidosis causing portal hypertension and recurrent variceal bleeding: a case report and review of the literature. Am J Clin Pathol. 2014;141(2):288–91.CrossRefPubMedGoogle Scholar
  29. 29.
    Chandan VS, Shah SS, Lam-Himlin DM, et al. Globular hepatic amyloid is highly sensitive and specific for LECT2 amyloidosis. Am J Surg Pathol. 2015;39:558–64.CrossRefPubMedGoogle Scholar
  30. 30.
    Kanel GC, Uchida T, Peters RL. Globular hepatic amyloid-an unusual morphologic presentation. Hepatology. 1981;1:647–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Agaram N, Shia J, Klimstra DS, et al. Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance. Hum Pathol. 2005;36:845–49.CrossRefPubMedGoogle Scholar
  32. 32.
    Makhlouf HR, Goodman ZD. Globular hepatic amyloid: an early stage in the pathway of amyloid formation. A study of 20 new cases. Am J Surg Pathol. 2007;31(10):1615–21.CrossRefPubMedGoogle Scholar
  33. 33.
    Pilgaard J, Fenger C, Schaffalitzky de Muckadell OB. Globular amyloid deposits in the liver. Histopathology. 1993;23(5):479–80.CrossRefPubMedGoogle Scholar
  34. 34.
    Demirhan B, Bilezikci B, Kiyici H, Boyacioglu S. Globular amyloid deposits in the wall of the gastrointestinal tract: report of six cases. Amyloid. 2002;9(1):42–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Hemmer PR, Topazian MD, Gertz MA, Abraham SC. Globular amyloid deposits isolated to the small bowel: a rare association with AL Amyloidosis. Am J Surg Pathol. 2007;31:141–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Comenzo RL. LECT2 makes the amyloid list. Blood. 2014;123(10):1436–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Picken MM. Alect2 amyloidosis: primum non nocere (first, do not harm). Kidney Int. 2014;86:229–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Oana Madalina Mereuta
    • 1
  • Chris P. Larsen
    • 2
  • Ahmet Dogan
    • 3
    Email author
  1. 1.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.NephropathLittle RockUSA
  3. 3.Departments of Pathology and Laboratory MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations